Arvinas reports Q3 2026 results, dosing starts in new HPK1 trial
Arvinas began dosing patients in a Phase 1/2 trial of its HPK1 degrader ARV-6723 and reaffirmed plans for data from three Phase 1 programs by 2027.
SEC filing (3)
1 story
Arvinas began dosing patients in a Phase 1/2 trial of its HPK1 degrader ARV-6723 and reaffirmed plans for data from three Phase 1 programs by 2027.
SEC filing (3)